Expert Blogger

The treatment of coronary artery disease has advanced significantly over the years, particularly with the evolution of minimally invasive procedures such as percutaneous coronary intervention (PCI). While stent technologies have dramatically improved patient outcomes, one challenge that remains relevant in interventional cardiology is in-stent restenosis (ISR).

ISR occurs when a previously treated coronary artery becomes narrowed again after stent implantation. Although modern stents have reduced restenosis rates considerably, repeat blockage within the stented segment can still occur and may require further intervention.

Traditionally, repeat stenting has been a common approach for ISR management. However, placing another stent within an already stented artery can increase vessel complexity and create additional layers of metal inside the artery. This has encouraged clinicians to explore treatment strategies that effectively manage restenosis without introducing another permanent implant.

In recent years, drug-coated balloons (DCBs) have emerged as one of the most promising approaches for ISR treatment. Their growing clinical adoption has led many experts to consider them a preferred treatment strategy in selected restenosis cases.

Understanding In-Stent Restenosis

In-stent restenosis is primarily caused by excessive tissue growth inside the stented segment, resulting in narrowing of the artery and reduced blood flow. Patients with ISR may experience recurrent chest pain, shortness of breath, or other symptoms associated with reduced coronary circulation.

Several factors can contribute to ISR, including:

• Complex coronary lesions
• Diabetes
• Small vessel disease
• Stent underexpansion
• Long lesion length
• Multiple overlapping stents

Managing ISR can often be more challenging than treating a fresh coronary blockage because the artery has already undergone prior intervention.

This is where DCB technology has started changing the conversation around restenosis management.

What Is a Drug-Coated Balloon?

A drug-eluting balloon is a specialized angioplasty balloon designed to deliver an antiproliferative drug directly to the vessel wall during balloon inflation. Unlike traditional stents, the balloon does not leave behind any permanent implant after the procedure.

The process generally involves:

• Preparing the restenotic lesion using balloon angioplasty
• Inflating the DCB at the target site
• Delivering the therapeutic drug into the vessel wall
• Removing the balloon after drug transfer

The key advantage of this approach is that it provides localized drug therapy without adding another metallic layer inside the artery.

This “leave-nothing-behind” strategy has become one of the biggest reasons behind the increasing popularity of DCB therapy in ISR management.

Why Drug-Coated Balloons Are Gaining Attention

Over the past decade, DCB therapy has gained strong clinical support through multiple studies and growing physician experience.

Several factors have contributed to its rise in modern interventional cardiology:

Avoiding Additional Stent Layers

One of the biggest advantages of a drug eluting balloon is that it treats the lesion without implanting another stent. This becomes particularly important in patients who already have multiple overlapping stents.

Improved Vessel Flexibility

Without an additional metallic scaffold, the artery may retain better natural flexibility and vessel dynamics after the procedure.

Localized Drug Delivery

DCBs deliver antiproliferative medication directly to the affected area, helping reduce tissue proliferation associated with restenosis.

Simpler Future Interventions

Since no permanent implant remains after treatment, future coronary interventions may become less complicated if additional procedures are needed later.

These benefits have contributed to the growing perception of DCB therapy as a preferred strategy for selected ISR cases.

Clinical Evidence Supporting DCB Therapy

The increasing adoption of DCBs is strongly supported by clinical research and long-term procedural outcomes.

Multiple studies have demonstrated the effectiveness of DCB therapy in reducing restenosis and repeat revascularization in ISR patients. Over time, clinical guidelines have also started recognizing DCBs as an evidence-based treatment option for ISR management.

The success of DCB technology reflects a broader shift in interventional cardiology toward therapies that combine procedural effectiveness with reduced long-term vessel burden.

Expanding Applications Beyond ISR

Although ISR remains one of the most established indications for DCB therapy, its use is gradually expanding into other coronary intervention scenarios.

Today, DCBs are also being explored in:

• Small vessel disease
• Bifurcation lesions
• Diffuse coronary disease
• High bleeding-risk patients
• Selected de novo lesions

As clinical experience grows, DCB therapy may continue to play a larger role in future PCI strategies.

The Growing Innovation Among Drug-Coated Balloon Manufacturers

The growing demand for DCB technology has encouraged significant innovation across the cardiovascular device industry. Today, several drug-coated balloon manufacturers are focusing on improving drug-transfer efficiency, balloon design, deliverability, and long-term procedural outcomes.

Manufacturers are increasingly investing in:

• Advanced coating technologies
• Improved balloon flexibility
• Uniform drug distribution systems
• Reduced drug loss during delivery
• Technologies for complex lesion treatment

These advancements are helping make DCB therapy more reliable and adaptable across different coronary anatomies.

The rapid pace of innovation among drug-coated balloon manufacturers also reflects the growing clinical importance of implant-free coronary intervention strategies.

Translumina’s Role in Drug-Coated Balloon Technology

Among companies advancing coronary intervention technology, Translumina offers drug-coated balloon solutions as part of its interventional cardiology portfolio. The company’s focus on coronary care technologies reflects the broader industry trend toward improving restenosis management through minimally invasive and implant-free treatment approaches.

As DCB adoption continues to grow globally, ongoing innovation in balloon engineering and drug-delivery systems is expected to further strengthen clinical outcomes in ISR treatment.

The Future of Restenosis Management

The future of ISR treatment is likely to move toward increasingly personalized and less invasive coronary intervention strategies. Physicians today are not only focused on procedural success but also on preserving long-term vessel health and reducing repeat interventions.

In this changing landscape, DCB therapy represents an important shift in how restenosis is approached. Rather than adding more metal to the artery, clinicians now have access to therapies that deliver effective treatment while preserving vessel anatomy.

This evolving philosophy is one of the key reasons why DCBs are increasingly being viewed as a new benchmark in ISR management.

Conclusion

In-stent restenosis continues to remain a complex challenge in interventional cardiology, despite major advancements in stent technology. However, the emergence of the drug-eluting balloon has introduced a powerful alternative for managing restenosis without adding another permanent implant.

By combining localized drug delivery with an implant-free treatment strategy, DCB therapy is reshaping how physicians approach ISR treatment in modern PCI procedures. At the same time, continued innovation among drug-coated balloon manufacturers is helping expand the possibilities of minimally invasive coronary intervention.

As clinical evidence and physician confidence continue to grow, DCB technology is expected to play an increasingly important role in the future of restenosis management.